CIRIUM
11.3.2021 07:27:13 CET | Business Wire | Press release
Cirium , the aviation analytics company, which is part of RELX, today announces the acquisition of Migacore , a travel technology start-up that has demonstrated how applying advanced machine learning (ML) techniques to online data sources can help airlines stay ahead of changes in passenger demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310006079/en/
Migacore has worked with some of the world’s most advanced carriers, such as Lufthansa and Singapore Airlines, to translate data from online news, search, social media, events and exhibitions, into signals that can help predict real-world travel demand.
After a series of successful airline trials, the Migacore team and technology are joining Cirium, which will help to scale the capabilities. The Migacore team will not only gain access to Cirium’s data and resources, but also to the group’s commercial reach across global aviation.
Airline demand models have traditionally been built around comparing current booking activity against historic trends, with the ticket offers raised or lowered to ensure that a flight is filled at optimum fare levels. The search was already on to improve on this but has been accelerated by the unprecedented collapse of flying during the pandemic.
“The airline industry has been experimenting with new sources of demand data for some time, but the pandemic has now made this an absolute necessity. Past booking patterns today give virtually no guide to current demand,” said Kevin O’Toole, chief strategy officer at Cirium.
“Migacore is not alone in looking for new demand signals, but it really stands out. Their airline partners were clearly impressed with how the team had taken time to understand and integrate with the highly automated workflow around Revenue Management. And we were impressed too,” said O’Toole.
“Integrating our forecasting capabilities into the Cirium portfolio will bring forward the new model that the market has needed for some time, allowing airlines to better forecast the intent to travel. Ultimately that means better matching between market demand and the airline offer, which should be good for travelers and carriers alike,” said Abheer Kolhatkar, chief executive officer and co-founder at Migacore.
The plan is to scale the existing service under the Cirium brand and to make similar forecasting available to clients across air travel and into aerospace, aircraft finance and beyond.
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
About RELX
RELX is a global provider of information-based analytics and decision tools for professional and business customers. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs over 33,000 people, of whom almost half are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX. The market capitalisation is approximately £33.3bn, €39bn, $46.5bn.
About Migacore
Migacore is a tech start-up founded and built by machine learning experts, focusing on bringing predictive demand forecasting for airlines. Migacore was one of the first start-ups to join IAG’s Hangar 51 program, is an alumni of Accelerate@IATA — a program led by IATA and Silicon Valley’s platform Plug and Play—and was one of the first start-ups to graduate from Singapore Airline’s KrisLab scheme. Migacore’s innovation has been featured heavily at key industry events including ATPCO’s Elevate events 2019 and 2018 , Applied Machine Learning Days (AMLD) 2020 , Entrepreneur First 2017 and NDR – The Artificial Intelligence Conference 2018 , and was named as Plug and Play’s 11 start-ups to watch for 2020 .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310006079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 15:00:00 CET | Press release
Renowned optimization and AI technologies leader to advance hybrid approaches for demanding decision challenges. Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remai
Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 14:00:00 CET | Press release
Alliance Brings Seamless Integration of Asset Data into ArcGIS for PIX4Dcatch Users Pix4D joins with Esri to launch new terrestrial scanning workflow for infrastructure-focused organizations. Esri and Pix4D workflow lets field teams capture accurate 3D models and augmented reality using PIX4Dcatch app data integrated directly into ArcGIS Online in real time. New integration enables users to document subsurface assets with seamless precision. Workflow brings high-fidelity, georeferenced documentation and instant verification to the project lifecycle for improved accuracy. Explore the PIX4Dcatch app and publish 3D data to ArcGIS Online. Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Es
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 14:00:00 CET | Press release
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 12:30:00 CET | Press release
Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRDCOMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profileIn COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3Clinically meaningful reduction in MADRS (≥ 25%) observed in significant number of participants in 25mg arm of both trials with 25% in COMP005 and 39% in COMP006Statistically significant rapid onset from the day following administration maintained at all measured timepoints through Week 6 in both clinical trials in the 25 mg armIn COMP005, participa
BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 12:00:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
